Tuesday, June 18, 2024

Psoriatic Arthritis Care in Canada: Novartis and Clarius Announce Partnership

Similar articles

Psoriatic arthritis care in Canada is set to improve significantly as Novartis Pharmaceuticals Canada partners with Clarius Mobile Health to enhance access to advanced ultrasound technology for detecting the condition in patients.

Under this agreement, Novartis and Clarius will provide rheumatologists with access to the Clarius L15 HD3 scanner, a handheld device designed to automatically deliver clear and detailed ultrasound images of superficial anatomy. This user-friendly scanner connects wirelessly to an AI-powered app on Apple and Android devices, facilitating seamless integration into clinical workflows.

The partnership goes beyond merely providing devices. Novartis and Clarius will also offer extensive training, support, and educational resources to rheumatologists. These will be delivered through various formats, including in-person sessions, virtual events, and asynchronous learning modules. This comprehensive approach ensures that healthcare professionals are well-equipped to utilize the technology effectively in their practice.

Novartis plans to create evidence to assess and monitor the adoption, usage, and impact of the ultrasound technology. This data-driven approach will help identify best practices for incorporating ultrasound into routine clinical practice, particularly for the early detection of PsA. By generating robust evidence, Novartis aims to demonstrate the value of ultrasound in improving patient outcomes and streamlining diagnostic processes.

Mark Vineis, President of Novartis Canada, emphasized the transformative potential of this partnership. “At Novartis, we recognize the tremendous potential AI holds for our industry and the healthcare landscape at large. The partnership with Clarius has the potential to transform PsA detection, with the possibility of scaling to other immunology indications, across specialties, and beyond Canada.”

Psoriatic arthritis

Psoriatic Arthritis Care: Novartis and Clarius Enhance Diagnostic Capabilities with Advanced Ultrasound Technology for Rheumatologists

Psoriatic arthritis is a chronic autoimmune disease that causes joint inflammation, leading to symptoms such as swelling, pain, and stiffness. Early and accurate diagnosis is crucial for managing the disease effectively and improving patient outcomes. By providing advanced ultrasound technology to rheumatologists, Novartis and Clarius aim to enhance the diagnostic capabilities and facilitate timely intervention for PsA patients.

You can follow our news on our Telegram and LinkedIn accounts.

Ohad Arazi, President and CEO of Clarius, expressed enthusiasm for the collaboration. “We are inspired by Novartis’ mission to improve care for PsA patients and their novel approach to help accelerate diagnosis with real-time ultrasound imaging. We believe that this type of partnership between a pharmaceutical and a medical technology company can play a tremendous role in improving patient outcomes and reducing the burden on our healthcare system.”

Earlier this year, Clarius Mobile Health received 510(k) clearance from the US Food and Drug Administration (FDA) for its Clarius Bladder AI, a non-invasive tool designed to automatically measure bladder volume. This regulatory milestone highlights Clarius’s commitment to developing innovative medical technologies that enhance diagnostic accuracy and patient care.

The partnership between Novartis Pharmaceuticals Canada and Clarius Mobile Health represents a significant advancement in the detection and management of psoriatic arthritis. By leveraging cutting-edge ultrasound technology and comprehensive support, this collaboration aims to improve early diagnosis and patient outcomes. The initiative also demonstrates the broader potential for AI-powered medical devices to transform healthcare practices across various specialties and regions.

As the healthcare landscape continues to evolve, partnerships like this one between Novartis and Clarius will play a critical role in driving innovation and ensuring that patients receive the best possible care. With the successful implementation of this initiative, the future looks promising for the integration of advanced diagnostic tools in routine clinical practice, ultimately benefiting patients and healthcare systems alike.

Resource: Clarius, May 27, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article